Katherine Stueland - Mar 26, 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Signature
/s/ Bridget Brown, Attorney-in-Fact
Stock symbol
WGS
Transactions as of
Mar 26, 2024
Transactions value $
-$1,117,566
Form type
4
Date filed
3/17/2025, 09:51 PM
Previous filing
Mar 19, 2024
Next filing
Apr 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Sale -$96.4K -1.08K -13.91% $89.44 6.67K Mar 13, 2025 Direct F1, F2
transaction WGS Class A Common Stock Options Exercise $0 +18.8K +280.94% $0.00 25.4K Mar 16, 2025 Direct F3
transaction WGS Class A Common Stock Sale -$1.02M -10.6K -41.53% $96.71 14.9K Mar 17, 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Restricted Stock Unit Award $0 +320K $0.00 320K Mar 26, 2024 Class A Common Stock 320K Direct F3, F5
transaction WGS Restricted Stock Unit Award $0 +47.7K $0.00 47.7K Mar 15, 2025 Class A Common Stock 47.7K Direct F3, F6
transaction WGS Restricted Stock Unit Options Exercise $0 -18.8K -11.11% $0.00 150K Mar 16, 2025 Class A Common Stock 18.8K Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.695 to $89.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.30 to $96.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 On March 26, 2024, Katherine Stueland was granted an RSU award for 320,000 RSUs. 25% of the underlying restricted stock units each vests annually, commencing on March 26, 2025, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F6 25% of the underlying restricted stock units each vests annually, commencing on March 15, 2026, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F7 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.